Centre de recherche du Centre hospitalier universitaire de Sherbrooke
usherbrooke.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
28
Active
6
Phase 3
4
Total enrollment
13,480
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Radiopharmaceutical 68Ga-DOTATATE | — | — | — | — | — | 1 | |
| Radiopharmaceutical 68Ga-PSMA | — | — | — | — | — | 1 |
Next readouts
- 2026-12-30
- 2027-12-15
Top conditions
- Neuroendocrine Tumors2
- COVID-192
- Acute Myeloid Leukemia1
- Septic Shock1
- Chronic Heart Failure1
- Cerebral Perfusion Pressure1
- Vasopressor Agents1
- Shock1
Frequently asked questions about Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- How many clinical trials does Centre de recherche du Centre hospitalier universitaire de Sherbrooke have on ClinicalTrials.gov?
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke is listed as the lead sponsor on 28 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre de recherche du Centre hospitalier universitaire de Sherbrooke's trials are in Phase 3?
- 4 of Centre de recherche du Centre hospitalier universitaire de Sherbrooke's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Centre de recherche du Centre hospitalier universitaire de Sherbrooke focus on?
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke's most-studied conditions on ClinicalTrials.gov are Neuroendocrine Tumors, COVID-19, Acute Myeloid Leukemia, Septic Shock, Chronic Heart Failure.
- When are Centre de recherche du Centre hospitalier universitaire de Sherbrooke's next clinical trial readouts?
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke has 2 upcoming primary-completion readouts tracked here; the soonest is “68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy”, expected around 2026-12-30.